ATE512228T1 - Induzierbare expressionssysteme - Google Patents

Induzierbare expressionssysteme

Info

Publication number
ATE512228T1
ATE512228T1 AT06824268T AT06824268T ATE512228T1 AT E512228 T1 ATE512228 T1 AT E512228T1 AT 06824268 T AT06824268 T AT 06824268T AT 06824268 T AT06824268 T AT 06824268T AT E512228 T1 ATE512228 T1 AT E512228T1
Authority
AT
Austria
Prior art keywords
rtta
inducable
expression systems
nucleic acid
acid molecules
Prior art date
Application number
AT06824268T
Other languages
English (en)
Inventor
Benjamin Berkhout
Atze Taede Das
Original Assignee
Tet Systems Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36013269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512228(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tet Systems Gmbh & Co Kg filed Critical Tet Systems Gmbh & Co Kg
Application granted granted Critical
Publication of ATE512228T1 publication Critical patent/ATE512228T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT06824268T 2005-11-17 2006-11-17 Induzierbare expressionssysteme ATE512228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05077623 2005-11-17
PCT/NL2006/000575 WO2007058527A2 (en) 2005-11-17 2006-11-17 Inducible expression systems

Publications (1)

Publication Number Publication Date
ATE512228T1 true ATE512228T1 (de) 2011-06-15

Family

ID=36013269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824268T ATE512228T1 (de) 2005-11-17 2006-11-17 Induzierbare expressionssysteme

Country Status (10)

Country Link
US (1) US8383364B2 (de)
EP (1) EP1954811B1 (de)
JP (1) JP5155176B2 (de)
AT (1) ATE512228T1 (de)
AU (1) AU2006316288B2 (de)
CA (1) CA2630348C (de)
DK (1) DK1954811T3 (de)
ES (1) ES2366227T3 (de)
NO (1) NO20082783L (de)
WO (1) WO2007058527A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
JP5155176B2 (ja) 2005-11-17 2013-02-27 ティーイーティー システムズ ゲーエムベーハー ウント ツェーオー． カーゲー 誘導発現系
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
DK1974017T4 (da) 2005-12-09 2023-09-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
US20130005590A1 (en) * 2011-06-06 2013-01-03 The Regents Of The University Of California Synthetic biology tools
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3172325B1 (de) 2014-07-22 2023-06-28 The University of Notre Dame du Lac Molekulare konstrukte und verwendungen davon
EP3344757A1 (de) 2015-09-04 2018-07-11 Universita' Degli Studi Di Padova Verfahren zur erzeugung von somatischen stammzellen
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP3856226B1 (de) 2018-09-28 2026-02-18 President and Fellows of Harvard College Zelluläre umprogrammierung zur umkehrung der alterung und zur förderung der organ- und geweberegeneration
EP3856260A1 (de) * 2018-09-28 2021-08-04 President and Fellows of Harvard College Mutante reverse tetracyclin-transaktivatoren zur expression von genen
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
EP0402402B1 (de) 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Hemmung von htlv-iii durch exogene oligonukleotide
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994008004A1 (en) 1992-10-05 1994-04-14 Hybridon, Inc. Therapeutic anti-hiv oligonucleotide and pharmaceutical
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1995006409A1 (en) 1993-09-03 1995-03-09 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) * 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
AU2002359666A1 (en) 2001-12-10 2003-06-23 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1458855B1 (de) 2001-12-18 2012-04-25 Cancer Research Technology Limited Methode zur herstellung von proliferierenden und differenzierenden zelllinien
JP2005521393A (ja) 2002-03-20 2005-07-21 マサチューセッツ インスティテュート オブ テクノロジー Ｈｉｖ治療
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
GB0327384D0 (en) * 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
WO2006132524A1 (en) 2005-06-06 2006-12-14 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for generating a t cell against an antigen of interest.
JP5155176B2 (ja) 2005-11-17 2013-02-27 ティーイーティー システムズ ゲーエムベーハー ウント ツェーオー． カーゲー 誘導発現系

Also Published As

Publication number Publication date
ES2366227T3 (es) 2011-10-18
CA2630348A1 (en) 2007-05-24
US8383364B2 (en) 2013-02-26
WO2007058527A3 (en) 2007-09-20
EP1954811B1 (de) 2011-06-08
CA2630348C (en) 2016-01-12
AU2006316288A1 (en) 2007-05-24
JP2009515550A (ja) 2009-04-16
WO2007058527A2 (en) 2007-05-24
NO20082783L (no) 2008-08-01
DK1954811T3 (da) 2011-07-04
EP1954811A2 (de) 2008-08-13
AU2006316288B2 (en) 2012-12-20
JP5155176B2 (ja) 2013-02-27
US20100040649A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
NO20082783L (no) Induserbare ekspresjonssystemer
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
EP4105644A3 (de) Systeme und vorrichtungen zur "sequence-by-synthesis"-analyse
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BRPI0414599A (pt) pirrol-indóis substituìdos
DK2207786T3 (da) 2´-Fluor-2´-deoxytetrahydrouridiner som cytidindeaminasehæmmere
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
DK1836299T4 (da) Polypeptider, der har cellobiohydrolaseaktivitet, og polynukleotider, der koder for disse
WO2009123762A3 (en) Method of screening single cells for the production of biologically active agents
MX2018005512A (es) Agentes de union de esclerostina.
EA200870619A1 (ru) Модифицированный фермент дикамба-монооксигеназа и способы его применения
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
EP2516624A4 (de) Zelllinie 3m
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
WO2007135685A3 (en) Compositions for silencing the expression of gibberellin 2-oxidase and uses thereof
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
NO20081470L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse.
EA201000069A1 (ru) Новые гербициды
ATE532861T1 (de) Expressionsvektor
EA200702193A1 (ru) Гликозилирование белков

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties